Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepiapterin versus Sapropterin in Phenylketonuria
2023-506238-61-00Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of sepiapterin in phenylketonuria (PKU) (2 arms), sponsored by PTC Therapeutics, Inc. Primary endpoint: Mean change in blood phenylalanine levels. Started May 2024; status: completed.
02
Drugs
sepiapterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on 2023-506238-61-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506238-61-00.